Related content

Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review

By Liu Shuyan   Yuan Zhengang   Zhang Chunyang   Fu Weijun   Hou Jian  

Oncology Letters, Vol. 4, Iss. 2, 2012-08 ,pp. : 262-264

Spandidos Publications

Access to resources Recommend Favorite

Use of rituximab in three children with relapsed/refractory Burkitt lymphoma

By Akbayram Sinan  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 291-294

Springer Publishing Company

Access to resources Recommend Favorite

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

By Harrison Simon J.   Hsu Andy K.   Neeson Paul   Younes Anas   Sureda Anna   Engert Andreas   Prince H. Miles   Li Martha   Savage Paula   Bugarini Roberto   Williams Denise   Squier Margaret   Ritchie David S.  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 1053-1060

Informa Healthcare

Access to resources Recommend Favorite

Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma

By Yao Yi-yun   Tang Yong   Zhu Qi   Zhuang Yan   Cheng Yi-min   Wang Lei   Zou Li-fang  

Leukemia and Lymphoma, Vol. 54, Iss. 6, 2013-06 ,pp. : 1194-1200

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib in mantle cell lymphoma

By Suh K Stephen   Goy Andre  

Future Oncology, Vol. 4, Iss. 2, 2008-04 ,pp. : 149-168

Future Medicine

Access to resources Recommend Favorite